

Apparent Founder Effect during the Early Years of the S (1978â€“1979)

AIDS Research and Human Retroviruses

16, 1463-1469

DOI: 10.1089/088922200750005985

Citation Report

#	ARTICLE	IF	CITATIONS
1	Sequence Note: Extreme Founder Effect in an HIV Type 1 Subtype A Epidemic among Drug Users in Svetlogorsk, Belarus. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 1299-1303.	1.1	51
2	Importation of Multiple HIV Type 1 Strains into West Papua, Indonesia (Irian Jaya). <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1655-1659.	1.1	14
3	Early Evolution of the Human Immunodeficiency Virus Type 1 Subtype C Epidemic in Rural Malawi. <i>Journal of Virology</i> , 2002, 76, 12890-12899.	3.4	62
4	The Evolution of Primate Lentiviruses and the Origins of AIDS. , 2002, , 65-96.		10
5	Diversity Considerations in HIV-1 Vaccine Selection. <i>Science</i> , 2002, 296, 2354-2360.	12.6	731
6	Segregation of Human Immunodeficiency Virus Type 1 Subtypes by Risk Factor in Australia. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4600-4604.	3.9	29
7	U.S. Human Immunodeficiency Virus Type 1 Epidemic: Date of Origin, Population History, and Characterization of Early Strains. <i>Journal of Virology</i> , 2003, 77, 6359-6366.	3.4	112
8	An HIV Type 1 Subtype B Founder Effect in Korea: gp160 Signature Patterns Infer Circulation of CTL-Escape Strains at the Population Level. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 631-641.	1.1	16
9	Two Percent of HIV-Positive U.S. Blood Donors Are Infected with Non-subtype B Strains. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1065-1070.	1.1	27
10	Enigmas and Paradoxes: the Genetic Diversity and Prevalence of the Primate Lentiviruses. <i>Current HIV Research</i> , 2004, 2, 113-125.	0.5	2
11	Sequencing-Based Detection of Low-Frequency Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by an RNA/DNA Heteroduplex Generator-Tracking Assay. <i>Journal of Virology</i> , 2004, 78, 7112-7123.	3.4	40
12	Human Immunodeficiency Virus Type 1 Superinfection Was Not Detected following 215 Years of Injection Drug User Exposure. <i>Journal of Virology</i> , 2004, 78, 94-103.	3.4	75
13	Comparative population dynamics of HIV-1 subtypes B and C: subtype-specific differences in patterns of epidemic growth. <i>Infection, Genetics and Evolution</i> , 2005, 5, 199-208.	2.3	68
14	The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form O2 (CRF02_AG) in West Central Africa may be related to its replicative fitness. <i>Retrovirology</i> , 2006, 3, 40.	2.0	79
15	Increasing genetic distance to HIV-1 subtype B and F1 consensus sequences in the Brazilian epidemic: A challenge for vaccine strategies based on central immunogens?. <i>Infection, Genetics and Evolution</i> , 2007, 7, 594-599.	2.3	5
16	Analysis of HIV Type 1 BF Recombinant Sequences from South America Dates the Origin of CRF12_BF to a Recombination Event in the 1970s. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 569-578.	1.1	13
17	Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic. <i>PLoS Genetics</i> , 2014, 10, e1004295.	3.5	45
18	The early spread and epidemic ignition of HIV-1 in human populations. <i>Science</i> , 2014, 346, 56-61.	12.6	515

#	ARTICLE	IF	CITATIONS
19	1970s and “Patient 0”™ HIV-1 genomes illuminate early HIV/AIDS history in North America. <i>Nature</i> , 2016, 539, 98-101.	27.8	177
20	Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. <i>Journal of Virology</i> , 2016, 90, 1244-1258.	3.4	13
21	HIV and SIV Evolution. , 2017, , 71-92.		2
22	Tracking SARS-CoV-2 in Sewage: Evidence of Changes in Virus Variant Predominance during COVID-19 Pandemic. <i>Viruses</i> , 2020, 12, 1144.	3.3	123
23	No evidence for distinct types in the evolution of SARS-CoV-2. <i>Virus Evolution</i> , 2020, 6, veaa034.	4.9	85
25	National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014. <i>Eurosurveillance</i> , 2017, 22, .	7.0	30
26	Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions. <i>PeerJ</i> , 2020, 8, e9255.	2.0	30
28	Toward a Theory of the Underpinnings and Vulnerabilities of Structural Racism: Looking Upstream from Disease Inequities among People Who Use Drugs. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7453.	2.6	4